Tango Therapeutics, Inc.
TNGX
$31.47
$1.334.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 56.99M | 62.38M | 66.50M | 24.30M | 40.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.99M | 62.38M | 66.50M | 24.30M | 40.99M |
| Cost of Revenue | 129.26M | 132.17M | 134.00M | 136.45M | 142.30M |
| Gross Profit | -72.27M | -69.78M | -67.50M | -112.15M | -101.31M |
| SG&A Expenses | 45.26M | 41.51M | 42.84M | 45.13M | 44.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.52M | 173.67M | 176.84M | 181.58M | 186.86M |
| Operating Income | -117.53M | -111.29M | -110.34M | -157.29M | -145.87M |
| Income Before Tax | -107.26M | -101.59M | -100.41M | -145.39M | -132.06M |
| Income Tax Expenses | -29.00K | 4.00K | 108.00K | 172.00K | 202.00K |
| Earnings from Continuing Operations | -107.23 | -101.59 | -100.52 | -145.57 | -132.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.23M | -101.59M | -100.52M | -145.57M | -132.26M |
| EBIT | -117.53M | -111.29M | -110.34M | -157.29M | -145.87M |
| EBITDA | -115.41M | -109.01M | -107.91M | -154.80M | -143.37M |
| EPS Basic | -0.82 | -0.86 | -0.92 | -1.33 | -1.21 |
| Normalized Basic EPS | -0.51 | -0.53 | -0.55 | -0.81 | -0.74 |
| EPS Diluted | -0.83 | -0.88 | -0.93 | -1.33 | -1.21 |
| Normalized Diluted EPS | -0.51 | -0.54 | -0.56 | -0.81 | -0.74 |
| Average Basic Shares Outstanding | 496.67M | 463.40M | 440.49M | 438.03M | 435.81M |
| Average Diluted Shares Outstanding | 503.49M | 470.22M | 447.31M | 438.03M | 435.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |